TY - JOUR
T1 - Uncovering the signalling, structure and function of the 20-HETE-GPR75 pairing
T2 - Identifying the chemokine CCL5 as a negative regulator of GPR75
AU - Pascale, Jonathan V.
AU - Park, Eon Joo
AU - Adebesin, Adeniyi Michael
AU - Falck, John R.
AU - Schwartzman, Michal Laniado
AU - Garcia, Victor
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health grants PO1034300 and HL139793 (MLS), diversity supplement to Victor Garcia HL139793‐1S, American Heart Association Scientist Development Grant (16SDG27090040) (EP) and by the Robert A. Welch Foundation (I‐0011) (JRF). We acknowledge Dr. William C. Sessa from Yale University for his guidance throughout this project.
Funding Information:
This work was supported by grants from the National Institutes of Health grants PO1034300 and HL139793 (MLS), diversity supplement to Victor Garcia HL139793-1S, American Heart Association Scientist Development Grant (16SDG27090040) (EP) and by the Robert A. Welch Foundation (I-0011) (JRF). We acknowledge Dr. William C. Sessa from Yale University for his guidance throughout this project.
Publisher Copyright:
© 2021 The British Pharmacological Society
PY - 2021/9
Y1 - 2021/9
N2 - Background and Purpose: The G-protein-coupled receptor GPR75 (Gq) and its ligand, the cytochrome P450-derived vasoactive eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE), are involved in the activation of pro-inflammatory and hypertensive signalling cascades contributing to diabetes, obesity, vascular dysfunction/remodelling, hypertension and cardiovascular disease. Little is known as to how, where and with what affinity 20-HETE interacts with GPR75. Experimental Approach: To better understand the pairing of 20-HETE and its receptor (GPR75), we used surface plasmon resonance (SPR) to determine binding affinity/kinetics. The PRESTO-Tango receptor-ome methodology for GPR75 overexpression was coupled with FLIPR Calcium 6 assays, homogeneous time-resolved fluorescence (HTRF) IP-1 and β-arrestin recruitment assays to determine receptor activation and downstream signalling events. Key Results: SPR confirmed 20-HETE binding to GPR75 with an estimated KD of 1.56 × 10−10 M. In GPR75-transfected HTLA cells, 20-HETE stimulated intracellular Ca2+ levels, IP-1 accumulation and β-arrestin recruitment, all of which were negated by known 20-HETE functional antagonists. Computational modelling of the putative ligand-binding pocket and mutation of Thr212 within the putative 20-HETE binding site abolished 20-HETE's ability to stimulate GPR75 activation. Knockdown of GPR75 in human endothelial cells nullified 20-HETE-stimulated intracellular Ca2+. The chemokine CCL5, a suggested GPR75 ligand, binds to GPR75 (KD of 5.85 × 10−10 M) yet fails to activate GPR75; however, it inhibited 20-HETE's ability to activate GPR75 signalling. Conclusions and Implications: We have identified 20-HETE as a high-affinity ligand for GPR75 and CCL5 as a low-affinity negative regulator of GPR75, providing additional evidence for the deorphanization of GPR75 as a 20-HETE receptor.
AB - Background and Purpose: The G-protein-coupled receptor GPR75 (Gq) and its ligand, the cytochrome P450-derived vasoactive eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE), are involved in the activation of pro-inflammatory and hypertensive signalling cascades contributing to diabetes, obesity, vascular dysfunction/remodelling, hypertension and cardiovascular disease. Little is known as to how, where and with what affinity 20-HETE interacts with GPR75. Experimental Approach: To better understand the pairing of 20-HETE and its receptor (GPR75), we used surface plasmon resonance (SPR) to determine binding affinity/kinetics. The PRESTO-Tango receptor-ome methodology for GPR75 overexpression was coupled with FLIPR Calcium 6 assays, homogeneous time-resolved fluorescence (HTRF) IP-1 and β-arrestin recruitment assays to determine receptor activation and downstream signalling events. Key Results: SPR confirmed 20-HETE binding to GPR75 with an estimated KD of 1.56 × 10−10 M. In GPR75-transfected HTLA cells, 20-HETE stimulated intracellular Ca2+ levels, IP-1 accumulation and β-arrestin recruitment, all of which were negated by known 20-HETE functional antagonists. Computational modelling of the putative ligand-binding pocket and mutation of Thr212 within the putative 20-HETE binding site abolished 20-HETE's ability to stimulate GPR75 activation. Knockdown of GPR75 in human endothelial cells nullified 20-HETE-stimulated intracellular Ca2+. The chemokine CCL5, a suggested GPR75 ligand, binds to GPR75 (KD of 5.85 × 10−10 M) yet fails to activate GPR75; however, it inhibited 20-HETE's ability to activate GPR75 signalling. Conclusions and Implications: We have identified 20-HETE as a high-affinity ligand for GPR75 and CCL5 as a low-affinity negative regulator of GPR75, providing additional evidence for the deorphanization of GPR75 as a 20-HETE receptor.
KW - 20-HETE
KW - CCL5
KW - GPR75
KW - cognate pairing
KW - receptor biology
UR - http://www.scopus.com/inward/record.url?scp=85107854477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107854477&partnerID=8YFLogxK
U2 - 10.1111/bph.15525
DO - 10.1111/bph.15525
M3 - Article
C2 - 33974269
AN - SCOPUS:85107854477
SN - 0007-1188
VL - 178
SP - 3813
EP - 3828
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 18
ER -